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Primary fallopian tube carcinomas are rare and account
for approximately 0.14–1.8% of female genital malig-
nancies [1]. Fallopian tube carcinoma most frequently
occurs in women between the ages of 40 and 60 years.
The most common histologic type is serous type, and
the staging system is similar to that of epithelial ovarian
carcinomas. We describe a woman who complained of
postmenopausal vaginal bleeding and had been previ-
ously diagnosed with serous papillary adenocarcinoma
of the endometrium; however, the final results revealed
primary fallopian tube carcinoma.
A 52-year-old postmenopausal woman, gravida 2,
para 2, presented with postmenopausal vaginal bleed-
ing. She sought help at a hospital where the endometrial
biopsy initially revealed no evidence of malignancy. She
received medical treatment, but the vaginal bleeding per-
sisted. A fractional endometrial biopsy was performed,
and adenocarcinoma of the endometrium of the papil-
lary serous type was noted. Immunohistochemical stud-
ies revealed strong positive reactivity of p53 protein.
The endocervical specimen was negative for malignancy.
She visited our gynecology department for help, and a
high level of CA-125 (200.7 unit/mL) was found. The
pelvic magnetic resonance imaging was performed before
the operation, and there was no evidence of abnormal
thickening or nodularity in the endometrium and no
significant lymphadenopathy in the pelvis (Figure 1A).
Two small fibroid tumors (15 and 10 mm in size) were
present in the myometrium. Early-stage endometrial
malignancy without tumor mass was suspected before
the operation. We performed staging laparotomy includ-
ing extrafascial total abdominal hysterectomy, bilateral
salpingo-oophorectomy, bilateral pelvic and paraaor-
tic lymph node dissection, infracolic omentectomy, and
peritoneal cytology. No gross lesions of the bivalved
uterus were noted. We also found that the left fallopian
tube was engorged with intact contour and papillary
contents (Figure 1B). Primary fallopian tube carcinoma
was suspected. The pathologic results confirmed the
diagnosis of stage Ic serous papillary adenocarcinoma
of the fallopian tube (Figure 2). Adjuvant chemotherapy
with a regimen of cyclophosphamide and carboplatin
was administered. The patient withstood six courses of
chemotherapy well, and the level of CA-125 decreased
to within the normal range. She was well followed up
at our outpatient department.
The most common presentation of primary fallop-
ian tube carcinoma is vaginal bleeding and discharge
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Figure 1. Left adnexal mass. (A) Preoperative T2-weighted
image showing a large uterine myoma (4.9×3.5×3.5 cm)
occupying the ventral aspect of the uterus, together with a
pedunculated mass (3.7×2.1 cm; arrow) protruding in the
left adnexa. (B) Gross appearance of specimen showing the
left adnexal tumor (arrow).
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(50–60%), followed by abdominal pain (30–49%) and
abdominal mass (12–61%) [2]. Fallopian tube carcinoma
spreads in much the same manner as epithelial ovarian
cancer. Approximately 80% of patients are diagnosed
during the advanced stages of the disease. Some rare
cases of primary fallopian tube carcinoma are even diag-
nosed when cerebral metastasis or subclavian lymph-
adenopathy develops [3]. Patients who are diagnosed
during the early stages are fortunate. The previous diag-
nosis of endometrial carcinoma of the serous papillary
type was thought to be caused by the tumor cells that
dropped into the uterine cavity. This is the reason why
the specimen was noted in the second fractional endo-
metrial biopsy.
Surgery is the definitive treatment and involves
total abdominal hysterectomy with bilateral salpingo-
oophorectomy and infracolic omentectomy. Controversy
exists regarding the role of routine lymphadenectomy.
Routine retroperitoneal sampling and node dissection
of the pelvic and paraaortic nodes are required. Post-
operative treatment includes adjuvant chemotherapy
and radiotherapy. There have been no randomized trials
of fallopian tube carcinoma treatment using radiother-
apy and chemotherapy. However, chemotherapy using
a platinum-containing regimen, including cisplatin/
carboplatin, paclitaxel-containing regimens and the stan-
dard combination of cyclophosphamide, adriamycin
and platinum, have been proved to be effective [4,5].
It is known that elevated serum CA-125 level is closely
related with the presence of disseminated cancer cells
in the peritoneal cavity. Koji et al [6] reported that 
CA-125 levels correlated with the advanced stages of
adenocarcinoma of the uterine corpus. Therefore, the
possibility of fallopian tube malignancy should be kept
in mind when diagnosing patients with elevated CA-125
levels without obvious endometrial lesions.
Results of a recent study revealed that no cancer or
hyperplasia was subsequently diagnosed among women
with endometrial thicknesses of less than 4 mm [7].
There were rare relationships between fallopian tube
cancers and endometrial cancers except for the BRCA
gene mutation [8]. Although the transvaginal ultrasono-
graphy and cervical cytologic examination results are
adequate for managing women with postmenopausal
vaginal bleeding, we should always consider the rare
event of tubal malignancy, when there is elevation of
CA-125 levels with no obvious endometrial thickening.
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Figure 2. Pathology of adnexal tumor. (A) Fallopian serous
papillary carcinoma and tumor-occupying lumen cavity (hema-
toxylin and eosin, 40×). (B) Transition zone of fallopian
serous papillary carcinoma progress, from left to right (hema-
toxylin and eosin, 100×).
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